Health
FDA Decision on Controversial Flu Shot
The FDA is set to decide on Moderna's mRNA-based flu shot, a first-of-its-kind product. The decision could significantly impact the biotech industry and public health strategies.
Coverage timeline — 1 article
NPR
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
2026-08-01 11:00 UTC